The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with diabetic macular edema (DME) who have previously responded to at least 2 ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two ...

Diabetic retinopathy is the number one preventable cause of blindness. To avoid it, simply take care of your diabetes. Two ...

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 ...

The Federal Circuit recently issued decisions in a pair of appeals that provide guidance about when international filers of abbreviated ...

Rezolute advances therapies for hypoglycemia with RZ358 and RZ402, showing efficacy in trials. Read why RZLT stock is a compelling, albeit cautious, investment.

Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) announced that the FDA has accepted for review a Biologics License Application, or BLA, for ...

The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and main ...

Kodiak Sciences Inc. (NASDAQ:KOD – Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling ...